Ozmosi | HS-10390 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

HS-10390

Alternative Names: HS-10390, HS 10390, HS10390
Clinical Status: Active
Latest Update: 2024-10-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hansoh BioMedical R&D Company
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HS-10390

Countries in Clinic: China

Active Clinical Trial Count: 5

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Glomerulonephritis|IgA Nephropathy|Kidney Diseases

Phase 1: Glomerulosclerosis, Focal Segmental

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05942625

 HS-10390-101

P1

Recruiting

Glomerulonephritis|IgA Nephropathy|Glomerulosclerosis, Focal Segmental

2024-02-16

54%

2023-07-14

Primary Endpoints|Treatments

NCT06635772

 HS-10390-201

P2

Not yet recruiting

IgA Nephropathy|Glomerulonephritis|Kidney Diseases

2025-12-01

50%

2024-10-11

Primary Endpoints|Treatments

CTR20230998

 CTR20230998

P1

Active, not recruiting

IgA Nephropathy|Glomerulosclerosis, Focal Segmental

None

2025-04-29

Patient Enrollment|Start Date|Treatments|Trial Status

CTR20243738

 CTR20243738

P1

Active, not recruiting

IgA Nephropathy

None

2025-04-29

Start Date

CTR20243735

 CTR20243735

P2

Recruiting

IgA Nephropathy

None

2025-09-14

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions